17th International Symposium on Translational Research in Oncology (TRANSONC)
Dr Dennis Slamon, UCLA, presenting at TRANSONC
PROGRAMME
Wednesday, 25th September 2024 Lansdowne Suite, Herbert Park Hotel
Registration from 08:30 RCPI 4 external CPD credits
09:00 – 09:15 Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital, Dublin
TARGETED THERAPIES – Large Molecule
Session Chair – Prof. Sara Hurvitz, Fred Hutch Cancer Center
09:15 – 09:45 Revisiting CD47 as a therapeutic target in solid tumour malignancies
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine
09:45 – 10:15 Biomarkers of response and resistance to Antibody Drug Conjugates: translational insights
Dr. Aditya Bardia, David Geffen School of Medicine UCLA and the UCLA Health Jonsson CCC
10:15 – 10:45 Zanidatamab: A novel HER-2 directed biparatopic monoclonal antibody and its development in breast and other tumors
Dr. Debasis Chakrabarti, Global Development Lead, Executive Director, Hematology and Oncology , Clinical Development, Jazz Pharmaceuticals, Philadelphia
10:45 – 11:00 Coffee break
TARGETED THERAPIES – SMALL Molecule
Session Chair – Prof. Sara Hurvitz, Fred Hutch Cancer Center
11:00 – 11:30 Tucatinib, a Reversible HER2 TKI, Augments the Activity of Trastuzumab and HER2-Targeting ADCs Through a Unique Mechanism of Action
Dr. Anita Kulukian, Senior Principal Scientist, Pfizer
11:30 – 12:00 Phase 3 postMONARCH trial of bemaciclib+fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer (ABC) following progression on prior CDK4/6 inhibitor plus endocrine therapy and Phase Ia/Ib EMBER study of Imlunestrant, an oral SERD, as Monotherapy and in Combination with Targeted Therapy in ER+, HER2- ABC
Dr. Lillian Smith, Sr. Vice President, Global Development Head, Breast Cancer, Loxo@Lilly, Eli Lilly
12:00 – 12:30 Targeting the PI3K/Akt/mTOR Pathway: PIKing the right strategy
Dr. Komal Jhaveri, Section Head, Endocrine Therapy Research Program; Clin. Dir., Early Drug Dev. Service; Patricia & James Cayne Chair for Junior Faculty, MSKCC
12:30 – 13:30 Lunch
BREAST CANCER: Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD
13:30 – 14:00 Radioligand therapy and solid tumours
Dr. Eirini Pectasides, Clinical Program Leader, Novartis Institutes for BioMedical Research
14:00 – 14:30 Copper depletion as therapeutic strategy for triple negative breast cancer: Updates
Dr. Linda T. Vahdat, Deputy Director, Section Chief, Med Onc, Hematology, Dartmouth Cancer Center
KEYNOTE PRESENTATION
14:30 – 15:15 Translational Implications of New ADC Targets in Breast Cancer and CDK 4/6 Update
Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology.
15:15 – 15:30 Coffee break
GI and Colon Cancer: Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD
15:30 – 16:00 Pancreas Cancer: Novel therapeutics for today and tomorrow
Dr. Eileen O’Reilly, MSKCC, Prof Medicine, Weill Cornell Medicine
16:00 – 16:30 Advanced HCC: TKI, PD(l)-1, CTLA-4 and more
Dr. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA
16:30-17:00 Systemic Therapy for Biliary Cancers: Who is First?
Dr. Ghassan Abou-Alfa, MSKCC, Prof, Cornell University, Adj Prof Med Diplomacy, Trinity College Dubli
Thursday, 26th September 2024 Lansdowne Suite, Herbert Park Hotel
Registration from 08:30 RCPI 4 external CPD credits
BiTES/T-CELL engagers: Session Chair – Prof. Mario Sznol, Yale School of Medicine
09:00 – 09:30 Advances in developing ImmTAC molecules: pioneering soluble TCR- based bispecifics
Dr Annelise Vuidepot, SVP – CTO and Head of Pipeline & Platform research, Immunocore
09:30 – 10:00 How to Increase the Impact of BiTE® Immune Therapy in Solid Tumors
Dr Pablo Martinez Rodriguez, Executive Medical Director for Global Development, Amgen
10:00 – 10:30 Tumor-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy “cold” tumors “hot”
Dr. Janelle Waite, Director, Cancer Immunology Research, Regeneron Pharmaceuticals
10:30 – 10:45 Discussion session
10:45 – 11:00 Coffee break
IMMUNOTHERAPY: Session Chair – Prof. Mario Sznol, Yale School of Medicine
11:00 – 11:30 Tumor Infiltrating Lymphocyte therapy in Solid Tumors—Focus on Next Generation TIL Treatment
Dr. Rodabe Amaria, Melanoma Medical Oncologist, MD Anderson Cancer Center
KEYNOTE PRESENTATION
11.30 – 12:15 Beyond Immune Checkpoint Blockade: Emerging Strategies
Prof. Tak Mak, Director, Campbell Family Institute for Breast Cancer Research, Department of Medical Biophysics, Ontario Cancer Institute of Princess Margaret Hospital; Professor, Department of Immunology, University of Toronto
12:15 – 13:15 Lunch
IMMUNOTHERAPY – VACCINES: Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD
13:15 – 13:45 Cancer Vaccines: From Treatment to Prevention
Prof. Nora Disis, Clinical Research Division, Fred Hutch Cancer Centre
13:45 – 14:15 Arenavirus-based Immunotherapy to Target Cancer
Dr. Thomas Bogenrieder, CMO, Abalos Therapeutics
14:15 – 14:45 Oncolytic Immunotherapy in Oncology: focus on melanoma
Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune
14:45 – 15:00 Coffee break
biomarkers: Session Chair – Prof. William Gallagher, University College Dublin & AICRI
15:00 – 15:30 AI for biomarker development, deployment, and validation
Jeff Leek, Chief Data Officer, VP, J. Orin Edson Foundation Chair of Biostatistics, Fred Hutchinson Cancer Center
15:30 – 16:00 Extracellular Vesicles and their Cargo: key biomarkers in liquid biopsies or too early to say?
Prof. Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin
16:00– 16:30 Decoding heterogeneity in TNBC: many shades of p53 mutants
Prof. Joshua LaBaer, Executive Director, Biodesign Institute, Arizona State University
Friday 27th September 2024 Lansdowne Suite, Herbert Park Hotel
Registration from 8:30 RCPI 6 external CPD credits
TUMOUR MICROENVIRONMENT I: Session Chair – Prof Robert Kerbel, University of Toronto
09:00 – 09:30 Immune-Mediated Extracellular Matrix Remodeling Promotes Tumor Resistance and Metastasis Following Anti-Cancer Therapy
Prof. Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center
09:30 – 10:00 Vaccination against the tumor vasculature – an anti-angiogenic adjuvant to immunotherapy
Prof. Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC
10:00 – 10:30 Making tumors vulnerable to immunity via optimized drug combinations
Prof. Patrycja Nowak-Sliwinska, Head of Molecular Pharmacology Group, Vice-president of the School of Pharmaceutical Sciences, University of Geneva
10:30 – 10:45 Coffee break
TUMOUR MICROENVIRONMENT II: Session Chair – Prof Robert Kerbel, University of Toronto
10:45– 11:15 The rising interest in using oncology drugs below the MTD: contribution of TME modulations in maintaining efficacy
Prof. Robert Kerbel, Sunnybrook Research Institute, University of Toronto
11:15 – 11:45 Reviving the Clinical Potential of Patient Derived Xenografts for Evaluating Immunotherapies by using Chick Embryos
Dr. Hon Leong, Dept Medical Biophysics, Sunnybrook Research Institute, University of Toronto
KEYNOTE PRESENTATION
11:45 – 12:30 Perspectives on the role of Innate immunity in the tumor microenvironment
Prof. Pam Ohashi, Director, Tumor Immunotherapy Program, Princess Margaret Cancer Centre
12:30 – 13:30 Lunch
Immunotherapy: Neoadjuvant v’s AdjuvanT
Session Chair – Dr. Dimitrios Tryfonopoulos, Medical Oncologist, Saint Savvas Anticancer Hospital, Athens
13:30 – 14:00 Immunotherapy Neoadjuvant v’s Adjuvant: Breast cancer
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
14:00 – 14:30 Immunotherapy Neoadjuvant v’s Adjuvant: Melanoma
Prof. John Haanen, Medical Oncology Dept. Netherlands Cancer Institute
14:30 – 15:00 Immunotherapy Neoadjuvant v’s Adjuvant: Lung cancer
Dr. Patrick Forde, Trinity St James Cancer Institute, Trinity College Dublin
15:00– 15:15 Coffee break
Mutant KRAS, Mutant p53 & MYC Overexpression: From Undruggable to Druggable
Session Chair:Prof Joe Duffy, St. Vincent’s University Hospital & University College Dublin
15:15 – 15:45 Drugging Difficult to Target Genes: Where are We? Where are We Going?
Prof. Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.
15:45 – 16:15 Innovative strategies for targeting the undruggable p53 in cancer therapy
Dr. Ecaterina Dumbrava, Dept. Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
16:15 – 16:45 Drugging Undruggable: Targeting MYC-driven Cancers with a Molecular Glue Degrader
Dr. Filip Janku, CMO, Monte Rosa Therapeutics Meeting ends
